Replies to post #95927 on Biotech Values

[DewDiligence]

So you're saying that AIS could be worthy of investing in given its link to LibiGel, correct?

I think LibiGel satisfies my requirement for being a “singularly exciting” product; however, in #msg-50151147, acgood noted the loophole in the AIS-BPAX partnership that could cause AIS to get stiffed for everything but a mid-single-digit royalty. Hence, I’m not convinced AIS is the right way to play LibiGel.